A Phase I, Open, Dose Escalation Trial With BI 836826 in Patients With Advanced Chronic Lymphocytic Leukaemia.
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2017
At a glance
- Drugs BI 836826 (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 17 Jul 2017 Status changed from active, no longer recruiting to completed.
- 22 Jun 2017 Planned End Date changed from 1 Jan 2017 to 11 Jul 2017.
- 22 Jun 2017 Planned primary completion date changed from 1 Jan 2017 to 23 Jun 2017.